Farshid Dayyani

39PUBLICATIONS
116CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Life cycle assessment and industrial ecologyPredictive and prognostic markersCancer geneticsSocial epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

|May 04, 2026
Impact of <i>UGT1A1*28</i> polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.

|Mar 14, 2026
Regional Therapies Utilized in Treating Unresectable Colorectal Adenocarcinoma with Peritoneal Metastases.

Shray Malik, Vanessa Le, Farshid Dayyani

|Feb 27, 2026
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Sakti Chakrabarti, Stacey A Cohen, Antony Tin

|Jan 04, 2026
Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers.

Rutika Mehta, Samuel Rivero-Hinojosa, Farshid Dayyani

|Dec 05, 2025
Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.

Garrett K Harada, Jino Park, Nicholas Peterson

Pageof 7

Frequent Collaborators

5 joint publications

Nadine Abi-Jaoudeh

5 joint publications

Aditya Mahadevan

3 joint publications

Dayantha M Fernando

3 joint publications

Gregory P Botta